These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16327657)

  • 1. [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings].
    Lassalle S; Cervera P; Hofman V; Mari M; Dellamonica P; Hofman P
    Ann Pathol; 2005 Sep; 25(4):309-17. PubMed ID: 16327657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?
    Cossarizza A; Mussini C; Viganò A
    Bioessays; 2001 Nov; 23(11):1070-80. PubMed ID: 11746223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.
    Carr A; Miller J; Law M; Cooper DA
    AIDS; 2000 Feb; 14(3):F25-32. PubMed ID: 10716495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    Pérez-Molina JA; Domingo P; Martínez E; Moreno S
    J Antimicrob Chemother; 2008 Aug; 62(2):234-45. PubMed ID: 18480167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome.
    Barbaro G
    Curr Pharm Des; 2007; 13(21):2208-13. PubMed ID: 17627554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HIV-lipodystrophy syndrome].
    Mauss S; Schmutz G
    Med Klin (Munich); 2001 Jul; 96(7):391-401. PubMed ID: 11494914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
    Brinkman K; Smeitink JA; Romijn JA; Reiss P
    Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy.
    Sevastianova K; Sutinen J; Greco D; Sievers M; Salmenkivi K; Perttilä J; Olkkonen VM; Wågsäter D; Lidell ME; Enerbäck S; Eriksson P; Walker UA; Auvinen P; Ristola M; Yki-Järvinen H
    Diabetes; 2011 Jul; 60(7):1894-900. PubMed ID: 21602514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
    Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
    Nolan D; John M; Mallal S
    Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
    Tierney EP; Hanke CW
    Arch Dermatol; 2010 Nov; 146(11):1279-82. PubMed ID: 21079066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review.
    Graham NM
    J Acquir Immune Defic Syndr; 2000 Oct; 25 Suppl 1():S4-11. PubMed ID: 11126425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy.
    Shikuma CM; Hu N; Milne C; Yost F; Waslien C; Shimizu S; Shiramizu B
    AIDS; 2001 Sep; 15(14):1801-9. PubMed ID: 11579242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.